553 related articles for article (PubMed ID: 15193700)
1. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?
Aukrust P; Damas JK; Solum NO
J Am Coll Cardiol; 2004 Jun; 43(12):2326-8. PubMed ID: 15193701
[No Abstract] [Full Text] [Related]
3. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
5. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
6. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention.
Welt FG; Rogers SD; Zhang X; Ehlers R; Chen Z; Nannizzi-Alaimo L; Phillips DR; Simon DI
Catheter Cardiovasc Interv; 2004 Feb; 61(2):185-9. PubMed ID: 14755809
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
8. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells.
May AE; Kälsch T; Massberg S; Herouy Y; Schmidt R; Gawaz M
Circulation; 2002 Oct; 106(16):2111-7. PubMed ID: 12379582
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
11. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
13. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.
Chandler AB; Earhart AD; Speich HE; Kueter TJ; Hansen J; White MM; Jennings LK
Thromb Res; 2010 Jan; 125(1):44-52. PubMed ID: 19487018
[TBL] [Abstract][Full Text] [Related]
14. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease.
Prasad KS; Andre P; Yan Y; Phillips DR
Curr Opin Hematol; 2003 Sep; 10(5):356-61. PubMed ID: 12913790
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand.
Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV
Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088
[TBL] [Abstract][Full Text] [Related]
17. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase.
Otterdal K; Pedersen TM; Solum NO
Thromb Res; 2004; 114(3):167-77. PubMed ID: 15342213
[TBL] [Abstract][Full Text] [Related]
18. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3).
Choi WS; Jeon OH; Kim DS
J Thromb Haemost; 2010 Jun; 8(6):1364-71. PubMed ID: 20230421
[TBL] [Abstract][Full Text] [Related]
19. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
20. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
